September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
Portulaca-based hair tonics are promising eco-friendly and effective cosmetic alternatives.
February 2009 in “Journal of The American Academy of Dermatology” Pulsed dye laser treatment was effective for a skin condition resistant to other treatments.
December 2018 in “Notulae Botanicae Horti Agrobotanici Cluj-Napoca” The journal covers diverse plant science research and is now published online quarterly.
January 2026 in “Chemistry & Biodiversity” Platycladus orientalis fruit extracts have antioxidant and enzyme-inhibiting properties, useful for health and food applications.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
June 2023 in “International Ayurvedic Medical Journal” Tridax procumbens is effective for wound healing.
12 citations
,
November 2023 in “Skin Appendage Disorders” JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
The document cannot be summarized as it is not provided or is unclear.
April 2022 in “Molecules” Teak leaf extract contains compounds that could help treat hair loss.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
2 citations
,
January 2025 in “Pharmaceutical Research” Angelica gigas Nakai root extracts may help with cancer, pain, memory loss, and metabolic issues.
1 citations
,
November 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Preserving and accessing historical research is crucial for ongoing scientific progress.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
December 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Certain herbs like stinging nettle, Indian gooseberry, and St. John's Wort can help improve hair growth and health.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
January 2024 in “Biochemistry Research International” Compounds from Ziziphus spina-christi roots show strong antibacterial and antioxidant potential.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.